{"disease":{"id":"heterozygous-familial-hypercholesterolemia","name":"heterozygous familial hypercholesterolemia"},"drugs":{"marketed":[{"drug_id":"caduet","indication_name":"Heterozygous Familial Hypercholesterolemia (HeFH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"lerodalcibep","indication_name":"heterozygous familial hypercholesterolemia (HeFH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lerochol","generic_name":"LERODALCIBEP","company_name":"Lib Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"Lerodalcibep works by modulating a specific biological pathway to lower cholesterol levels."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03814187","title":"Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03694197","title":"Long Term Safety Study of PRALUENT","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":1389,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT03397121","title":"Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":482,"lead_sponsor_name":"The Medicines Company","has_results":true},{"nct_id":"NCT04797104","title":"Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":478,"lead_sponsor_name":"LIB Therapeutics LLC","has_results":false},{"nct_id":"NCT01968980","title":"A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":370,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04666298","title":"Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07427472","title":"\"Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)\"","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06958315","title":"Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06634160","title":"Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT02976818","title":"Lp(a) and Aortic Valve Calcification","phase":"","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Laval University","has_results":false},{"nct_id":"NCT02392559","title":"Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07058077","title":"A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":153,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04179669","title":"Safety and Efficacy of IBI306 in HeFH Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT05325203","title":"A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT02460159","title":"A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT07465263","title":"A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":135,"lead_sponsor_name":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","has_results":false},{"nct_id":"NCT05682378","title":"Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":131,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03038022","title":"Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Madrigal Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04173793","title":"A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT07470723","title":"The ORIGIN-FH Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT02326220","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT01576484","title":"Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT03563547","title":"Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia","phase":"NA","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Austrian Academic Institute for Clinical Nutrition","has_results":false},{"nct_id":"NCT04759534","title":"Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Shenzhen People's Hospital","has_results":false},{"nct_id":"NCT05398029","title":"A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Verve Therapeutics, Inc.","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}